• FDA Approves First Treatment for Rare Blood Disease americanpharmaceuticalreview
    December 24, 2018
    The U.S. Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.....
PharmaSources Customer Service